|
Market Closed -
Other stock markets
|
Pre-market 08:37:23 | |||
| 129.93 USD | +9.30% |
|
132.76 | +2.18% |
| 06:50am | Incyte Receives European Commission Approval for Opzelura Cream for Moderate Atopic Dermatitis in Adults | CI |
| 07-28 | Top Midday Gainers | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 25.96B | |||||
| 70.73B | |||||
| 54.27B | |||||
| 49.28B | |||||
| 39.94B | - | ||||
| 30.36B |
- Stock Market
- Stocks
- INCY Stock
- Charts Incyte Corporation
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
